Nebivolol-Induced Hepatoxicity: A Case Report

Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release. Nebivolol, despite its favourable safety profile, can lead to significant liver injury. We describe the case of a 7...

Full description

Saved in:
Bibliographic Details
Published in:European journal of case reports in internal medicine 2024-10, Vol.11 (11), p.004866
Main Authors: Srour, Lynn, Ali, Majed, Karam, Karam, Fiani, Elias
Format: Article
Language:English
Subjects:
hepatotoxicity
nebivolol
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nebivolol is a third-generation beta-blocker known for its high selectivity for beta-1 adrenergic receptors and its unique ability to induce vasodilation via nitric oxide (NO) release. Nebivolol, despite its favourable safety profile, can lead to significant liver injury. We describe the case of a 73-year-old hypertensive patient who developed significant liver enzyme elevations following the addition of nebivolol to her treatment regimen. Comprehensive workup ruled out other causes, leading to a diagnosis of drug-induced hepatotoxicity. Discontinuation of nebivolol resulted in normalization of liver enzymes. This case underscores the importance of monitoring liver function during beta-blocker therapy, particularly with nebivolol. Nebivolol, despite its favourable safety profile, can lead to significant liver injury.Clinicians should remain vigilant and consider routine liver function monitoring in patients prescribed nebivolol, particularly if they present with nonspecific symptoms or abnormal liver enzyme tests.Early recognition and prompt discontinuation of the offending agent are crucial in preventing severe outcomes.
ISSN:2284-2594
2284-2594
DOI:10.12890/2024_004866